Free tool
FAERS Monitor: Omidria
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205388 or its brand name (Omidria, Ketorolac Tromethamine, Phenylephrine Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
82
Serious
47
57% of reports
Hospitalization
2
Death reported
1
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- endophthalmitis19
- toxic anterior segment syndrome17
- corneal oedema15
- anterior chamber inflammation5
- corneal opacity4
- fibrin4
- hypopyon4
- iritis4
- keratitis4
- uveitis4
- vitritis4
- anterior chamber disorder3
- drug effect prolonged3
- intraocular pressure increased3
- pain3
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2015 | 1 |
| 2016 | 18 |
| 2017 | 16 |
| 2018 | 6 |
| 2019 | 6 |
| 2020 | 8 |
| 2021 | 6 |
| 2022 | 3 |
| 2023 | 9 |
| 2024 | 1 |
| 2025 | 8 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,054,077 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| fibrinSignal | 4 | 26334.1 | 9629.7 | 73,140 |
| toxic anterior segment syndromeSignal | 17 | 4064.1 | 2650.5 | 64,042 |
| anterior chamber disorderSignal | 3 | 3393.3 | 1109.0 | 6,972 |
| anterior chamber inflammationSignal | 5 | 2175.9 | 927.0 | 8,730 |
| corneal oedemaSignal | 15 | 1728.6 | 1092.0 | 24,041 |
| drug effect prolongedSignal | 3 | 1403.0 | 460.6 | 2,902 |
| hypopyonSignal | 4 | 1246.4 | 478.1 | 3,792 |
| endophthalmitisSignal | 19 | 815.0 | 549.1 | 14,601 |
| corneal opacitySignal | 4 | 754.1 | 289.5 | 2,296 |
| vitritisSignal | 4 | 555.5 | 213.3 | 1,691 |
| iritisSignal | 4 | 337.9 | 129.9 | 1,027 |
| keratitisSignal | 4 | 337.9 | 129.9 | 1,027 |
| uveitisSignal | 4 | 75.7 | 29.1 | 225 |
| intraocular pressure increasedSignal | 3 | 60.2 | 19.8 | 121 |
| pain | 3 | 1.3 | 0.4 | 0 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.